B-cell receptor recognizing diphtheria toxoid epitopes (BCR)

The B-cell receptor (BCR) recognizing diphtheria toxoid epitopes is a specialized surface immunoglobulin complex that mediates the recognition of inactivated diphtheria toxin. This receptor is composed of a membrane-bound antibody molecule associated with the CD79a and CD79b signaling subunits, which together initiate B-cell activation upon antigen binding (StatPearls, 2023). In the context of immunization, these BCRs are the primary targets for diphtheria toxoid-containing vaccines, such as DTaP and Tdap, which stimulate the production of protective neutralizing antibodies (CDC, 2022). Furthermore, the diphtheria toxoid derivative CRM197 is frequently utilized as a carrier protein in conjugate vaccines; it binds to these specific BCRs to facilitate antigen internalization and subsequent T-cell-dependent immune responses (PubMed, 2021). The interaction between the toxoid and the BCR is fundamental to establishing long-term humoral immunity against Corynebacterium diphtheriae infections. Clinically, the presence and frequency of B cells expressing these receptors serve as vital indicators of vaccine-induced immunity and overall immunocompetence (NIH, 2020).

Other names

Diphtheria toxoid-specific B-cell receptorDT-specific BCRAnti-diphtheria toxoid surface immunoglobulinAntigen-specific B-cell receptor

The diphtheria toxoid acts as an antigen that binds to and cross-links the B-cell receptor, initiating a signal transduction cascade through the Ig-alpha/Ig-beta (CD79A/CD79B) heterodimer. This process promotes B-cell internalization of the antigen, presentation to T-helper cells, and subsequent differentiation into plasma cells that secrete neutralizing antibodies against the diphtheria toxin.